Abstract

&#9660Linezolid* (Zyvox - Pharmacia) - the first oxazolidinone antibacterial - is marketed in the UK for treating hospital- and community-acquired pneumonia, skin and soft tissue infections. The manufacturer claims that switching from i.v. to oral administration of linezolid needs no dose adjustment and "will lead to early patient discharge and reduced hospital length of stay" for patients needing treatment for infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).1 Here, we assess the place of linezolid.